Related references
Note: Only part of the references are listed.Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review
Sara Elena Rebuzzi et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2020)
Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients
Ying Xiong et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
Matthew Labriola et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (10) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).
Yasser Ged et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).
A. Ari Hakimi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
The microbiome, cancer, and cancer therapy
Beth A. Helmink et al.
NATURE MEDICINE (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha et al.
GENOME MEDICINE (2019)
Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (SIR) metastatic renal cell carcinoma (m RCC).
Ziad Bakouny et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
Sarah Abou Alaiwi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
The Microbiome and Genitourinary Cancer: A Collaborative Review
Mark C. Markowski et al.
EUROPEAN UROLOGY (2019)
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A. Ari Hakimi et al.
CANCER DISCOVERY (2019)
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
Vinay Mathew Thomas et al.
CASE REPORTS IN ONCOLOGY (2019)
Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH 'Grupo Centro' of Genitourinary Tumors
A. Pinto et al.
KIDNEY CANCER (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell et al.
CELL (2018)
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2018)
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma
Xin Gao et al.
CLINICAL GENITOURINARY CANCER (2018)
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2018)
A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma
Todd M. Morgan et al.
EUROPEAN UROLOGY (2018)
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Robert J. Motzer et al.
EUROPEAN UROLOGY (2018)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Christopher J. Ricketts et al.
CELL REPORTS (2018)
Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.
Pavlos Msaouel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
Martin H. Voss et al.
LANCET ONCOLOGY (2018)
Tracing Renal Cell Carcinomas back to the Nephron
David Lindgren et al.
TRENDS IN CANCER (2018)
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study
Amishi Y. Shah et al.
BJU INTERNATIONAL (2017)
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
James J. Hsieh et al.
EUROPEAN UROLOGY (2017)
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2017)
Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma
Thai Huu Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Giovanni Germano et al.
NATURE (2017)
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Toni K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma
Wenhua Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Yi-Feng Gu et al.
CANCER DISCOVERY (2017)
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review
Bum Jun Kim et al.
ONCOTARGET (2017)
Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
Andrew W. Hahn et al.
ONCOTARGET (2017)
Renal Medullary Carcinoma: Establishing Standards in Practice
Kathryn E. Beckermann et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.
Bernardi. Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Remi Adelaiye-Ogala et al.
CANCER RESEARCH (2017)
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Zixing Wang et al.
CLINICAL CANCER RESEARCH (2017)
MET in human cancer: germline and somatic mutations
Elizabeth A. Tovar et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Jozefina Casuscelli et al.
JCI INSIGHT (2017)
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma
Li Liu et al.
BJU INTERNATIONAL (2016)
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
Jeffrey S. Ross et al.
CANCER (2016)
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma
Rochelle L. Tiedemann et al.
ONCOTARGET (2016)
DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Gabriel G. Malouf et al.
CLINICAL CANCER RESEARCH (2016)
Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2016)
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations
Gabriel G. Malouf et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
Peter A. Humphrey et al.
EUROPEAN UROLOGY (2016)
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Andre P. Fay et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer
Joanna Boguslawska et al.
JOURNAL OF UROLOGY (2016)
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
Richard W. Joseph et al.
JOURNAL OF UROLOGY (2016)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Mark Bi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities
Scott M. Haake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
A four-gene signature predicts survival in clear-cell renal-cell carcinoma
Jun Dai et al.
ONCOTARGET (2016)
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
Gabriel G. Malouf et al.
SCIENTIFIC REPORTS (2016)
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies
Xiangming Cheng et al.
BMC UROLOGY (2016)
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Courtney Hodges et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response
Thai H. Ho et al.
EUROPEAN UROLOGY FOCUS (2016)
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
Mark Agulnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Ian J. Frew et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10 (2015)
Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors
Sumanta K. Pal et al.
CLINICAL CANCER RESEARCH (2015)
A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma
Yueping Zhan et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2015)
Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature
Sebastian Ciszewski et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2015)
Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation
Siraj M. Ali et al.
EUROPEAN UROLOGY (2015)
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies
Brian Rini et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
N. Kanu et al.
ONCOGENE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation
Mehrad Adibi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
RNA-seq Reveals Aurora Kinase-Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Sumanta K. Pal et al.
MOLECULAR CANCER RESEARCH (2015)
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma
Steffen Durinck et al.
NATURE GENETICS (2015)
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
M. H. Voss et al.
ANNALS OF ONCOLOGY (2014)
Loss of BAP1 Protein Expression Is an Independent Marker of Poor Prognosis in Patients With Low-Risk Clear Cell Renal Cell Carcinoma
Richard W. Joseph et al.
CANCER (2014)
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Caleb F. Davis et al.
CANCER CELL (2014)
MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges et al.
CLINICAL CANCER RESEARCH (2014)
Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes
Gabriel G. Malouf et al.
CLINICAL CANCER RESEARCH (2014)
ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Samira A. Brooks et al.
EUROPEAN UROLOGY (2014)
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
Lucy Gossage et al.
GENES CHROMOSOMES & CANCER (2014)
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects
Jeremy M. Simon et al.
GENOME RESEARCH (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
Eric C. Kauffman et al.
NATURE REVIEWS UROLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Regulation and Role of EZH2 in Cancer
Hirohito Yamaguchi et al.
CANCER RESEARCH AND TREATMENT (2014)
Renal Medullary Carcinoma Molecular, Immunohistochemistry, and Morphologic Correlation
Qingyan Liu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma
N. Pecuchet et al.
ANNALS OF ONCOLOGY (2013)
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
Nils Kroeger et al.
CANCER (2013)
A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis
Massimo Masiero et al.
CANCER CELL (2013)
Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm
Samuel Pena-Llopis et al.
CANCER RESEARCH (2013)
The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα
Feng Li et al.
CELL (2013)
Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Gabriel G. Malouf et al.
CLINICAL CANCER RESEARCH (2013)
The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2013)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
A. Ari Hakimi et al.
CLINICAL CANCER RESEARCH (2013)
Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma
A. Ari Hakimi et al.
EUROPEAN UROLOGY (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
Payal Kapur et al.
LANCET ONCOLOGY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Integrated molecular analysis of clear-cell renal cell carcinoma
Yusuke Sato et al.
NATURE GENETICS (2013)
Renal Cell Carcinoma Associated With Transcription Factor E3 Expression and Xp11.2 Translocation Incidence, Characteristics, and Prognosis
Tobias Klatte et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship
Ruta Gupta et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Translocation Renal Cell Carcinomas in Adults: A Single-institution Experience
Minghao Zhong et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series
Alessandro Volpe et al.
BJU INTERNATIONAL (2012)
Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor Biology
A. Rose Brannon et al.
EUROPEAN UROLOGY (2012)
SMARCB1/INI1 inactivation in renal medullary carcinoma
Julien Calderaro et al.
HISTOPATHOLOGY (2012)
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma
Guangwu Guo et al.
NATURE GENETICS (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies
Brian Shuch et al.
ONCOLOGIST (2012)
Expression of EZH2 in renal cell carcinoma as a novel prognostic marker
Hye Won Lee et al.
PATHOLOGY INTERNATIONAL (2012)
ALK Rearrangement in Sickle Cell Trait-Associated Renal Medullary Carcinoma
Adrian Marino-Enriquez et al.
GENES CHROMOSOMES & CANCER (2011)
Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience
N. M. Tannir et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela et al.
NATURE (2011)
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
G. G. Malouf et al.
ANNALS OF ONCOLOGY (2010)
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Nina Wagener et al.
BMC CANCER (2010)
Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma
Toni K. Choueiri et al.
CANCER (2010)
External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology
Richard Zigeuner et al.
EUROPEAN UROLOGY (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
Complications Associated with Sickle Cell Trait: A Brief Narrative Review
Geoffrey Tsaras et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Polybromo-1: The chromatin targeting subunit of the PBAF complex
Martin Thompson
BIOCHIMIE (2009)
Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
Tobias Klatte et al.
CLINICAL CANCER RESEARCH (2009)
SWI/SNF Regulates the Cellular Response to Hypoxia
Niall S. Kenneth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
Rafal Stec et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
The SWI/SNF complex and cancer
D. Reisman et al.
ONCOGENE (2009)
Genetic and epigenetic alterations in the von Hippel-Lindau gene: The influence on renal cancer prognosis
Kim M. Smits et al.
CLINICAL CANCER RESEARCH (2008)
The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation
Sunnie M. Yoh et al.
GENES & DEVELOPMENT (2008)
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
Jean-Jacques Patard et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells
Nina Wagener et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma
Masahiro Yao et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF UROLOGY (2008)
Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior
Jason X. Cheng et al.
MODERN PATHOLOGY (2008)
Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array
Marieta I. Toma et al.
NEOPLASIA (2008)
Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation
John W. Edmunds et al.
EMBO JOURNAL (2008)
Segmental disorders of the nephron: histopathological and imaging perspective
S. R. Prasad et al.
BRITISH JOURNAL OF RADIOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Multi-institutional validation of a new renal cancer-specific survival nomogram
Pierre I. Karakiewicz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival analysis of 130 patients with papillary renal cell carcinoma:: Prognostic utility of type 1 and type 2 subclassification
Geraldine Pignot et al.
UROLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status
Brian I. Rini et al.
BJU INTERNATIONAL (2006)
Determination of vhl gene mutations in sporadic renal cell carcinoma
Jose Miguel Gimenez-Bachs et al.
EUROPEAN UROLOGY (2006)
Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation
TD Jones et al.
CANCER (2005)
Sarcomatoid renal cell carcinoma - An examination of underlying histologic subtype and an analysis of associations with patient outcome
JC Cheville et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An International Multicenter Study
JJ Patard et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Role of VHL gene mutation in human cancer
WY Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
A Zisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score
I Frank et al.
JOURNAL OF UROLOGY (2002)
Histone methyltransferase activity of a Drosophila polycomb group repressor complex
J Müller et al.
CELL (2002)
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma:: Relationship to clinicopathological parameters
K Kondo et al.
GENES CHROMOSOMES & CANCER (2002)
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma
P Schraml et al.
JOURNAL OF PATHOLOGY (2002)
Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases
MB Amin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma -: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents
P Argani et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Improved prognostication of renal cell carcinoma using an integrated staging system
A Zisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
